Alisa Lask - 05 Jan 2023 Form 4 Insider Report for NEPHROS INC (NEPH)

Role
Director
Signature
/s/ Christopher Melsha as attorney-in-fact for Alisa Lask pursuant to power of attorney previously filed.
Issuer symbol
NEPH
Transactions as of
05 Jan 2023
Transactions value $
$0
Form type
4
Filing time
09 Jan 2023, 15:33:11 UTC
Previous filing
12 Aug 2022
Next filing
11 Jul 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NEPH Common Stock Award $0 +27,613 +236% $0 39,338 05 Jan 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NEPH Stock Option (right to buy) Award $0 +7,080 $0 7,080 05 Jan 2023 Common Stock 7,080 $1.07 Direct F4
holding NEPH Stock Option (right to buy) 9,617 05 Jan 2023 Common Stock 9,617 $5.22 Direct F2
holding NEPH Stock Option (right to buy) 5,568 05 Jan 2023 Common Stock 5,568 $8.57 Direct F2
holding NEPH Stock Option (right to buy) 6,850 05 Jan 2023 Common Stock 6,850 $8.06 Direct F2
holding NEPH Stock Option (right to buy) 7,062 05 Jan 2023 Common Stock 7,062 $6.82 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of restricted stock granted to the reporting person in lieu of cash fees payable to the reporting person for her service on the Company's Board of Directors for 2022. These shares of restricted stock vest 6 months following the grant date.
F2 Fully exercisable.
F3 This option vests as to 2,354 shares on each of 12/14/21, 12/14/22 and 12/14/23.
F4 Represents options granted to the reporting person for her service on the Company's Board of Directors for 2022. This option vests as to 2,360 shares on each of 1/5/23, 1/5/24 and 1/5/25.